Advertisement

Optimized Treatment Strategy for Depressive Disorder

  • Peijun ChenEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1180)

Abstract

Despite many advances in pharmacotherapy over the past half centurye, only a fraction of patients with Major Depressive Disorder (MDD) can achieve remission after the first or second trial of pharmacotherapy. Those who failed standard antidepressant treatment are termed as Treatment-Resistant Depression (TRD). Pharmacotherapy for TRD is more viable over past 15 years in part due to advances in clinical trials such as the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) and the US Department of Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) study. In general, optimizing pharmacotherapy consists of switching to different agents, combination with different antidepressants, or augmentation with different class of psychotropic medications, and the latter is preferred. Augmenting agents with strong evidence include Bupropion, Lithium, Triiodothyronine (T3), Aripiprazole, Brexpiprazole, Quetiapine, and Olanzapine in combination with Fluoxetine. Many works need to be done to further advance this field. These include (1) Establish agreement on a standardized, systematic, and feasible definition of TRD, (2) Establish safety and tolerability beyond acute treatment phase, (3) Establish individual psychosocial and neurobiological marks such as pharmacogenetic variance, and (4) Utilize multi-treatment modules such as combination of psychotherapy and pharmacotherapy in conjunction with brain stimulation therapy such as electroconvulsive therapy, vagus nerve stimulation and transcranial magnetic stimulation; as well as non-traditional therapy such as nutritional supplements, exercise and light therapy.

Keywords

Treatment-resistant depression Risk factors Pharmacotherapy Augmentation 

References

  1. Aronson R, Offman HJ, Joffe RT, Naylor CD (1996) Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 53:842–848PubMedCrossRefPubMedCentralGoogle Scholar
  2. Barbee JG, Jamhour NJ (2002) Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 63:737–741PubMedCrossRefGoogle Scholar
  3. Bauer M, Dell’osso L, Kasper S, Pitchot W, Dencker Vansvik E, Köhler J, Jørgensen L, Montgomery SA (2013) J Affect Disord 151(1):209–219. Epub 27 Jun 2013Google Scholar
  4. Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M (2014) Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 28(4):331–342, Apr 2014PubMedCrossRefGoogle Scholar
  5. Bedson E, Bell D, Carr D, Carter B, Hughes D, Jorgensen A, Lewis H, Lloyd K, McCaddon A, Moat S, Pink J (2014) Folate augmentation of Treatment–Evaluation for Depression (FolATED): randomised trial and economic evaluation. Health Technol Assess 18:1–159CrossRefGoogle Scholar
  6. Bennabi D, Aouizerate B, El-Hage W, Doumy O, Moliere F, Courtet P et al (2014) Risk factors for treatment resistance in unipolar depression: a systematic review. J Affect Disord 171C:137–141Google Scholar
  7. Berent D, Zboralski K, Orzechowska A, Gałecki P (2014) Thyroid hormones association with depression severity and clinical outcome in patients with major depressive disorder. Mol Biol Rep 41(4):2419–2425PubMedPubMedCentralCrossRefGoogle Scholar
  8. Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hébert C, Debonnel G (2009) Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 19:457–465PubMedCrossRefGoogle Scholar
  9. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R (2010) Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167:281–288PubMedCrossRefGoogle Scholar
  10. Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME (2014) Efficacy and safety of olanzapine/fluoxetine combination vs. fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology 39(11):2549–2559PubMedPubMedCentralCrossRefGoogle Scholar
  11. Bschor T, Kern H, Henssler J, Baethge C (2018) Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. J Clin Psychiatry 79(1):16r10749CrossRefGoogle Scholar
  12. Carpenter LL, Yasmin S, Price LH (2002) A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51:183–188PubMedCrossRefGoogle Scholar
  13. Cheon EJ, Lee KH, Park YW, Lee JH, Koo BH, Lee SJ, Sung HM (2017) Comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study. J Clin Psychopharmacol 37(2):193PubMedCrossRefGoogle Scholar
  14. Citrome L (2010) Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 122:39–48PubMedCrossRefGoogle Scholar
  15. Citrome L (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Int J Clin Pract 69:978–997PubMedCrossRefGoogle Scholar
  16. Cowen PJ (2017) Backing into the future: pharmacological approaches to the management of resistant depression. Psychol Med 47(15):2569–2577PubMedPubMedCentralCrossRefGoogle Scholar
  17. Crossley NA, Bauer M (2007) Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 68:935–940PubMedCrossRefGoogle Scholar
  18. Demyttenaere K, Van Duppen Z (2019) The impact of (the concept of) treatment-resistant depression: an opinion review. Int J Neuropsychopharmacol 22(2):85–92PubMedCrossRefGoogle Scholar
  19. Fava M, Rush AJ, Wisniewski SR et al (2006) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163(7):1161–1172PubMedCrossRefGoogle Scholar
  20. Fornaro M, Martino M, Mattei C, et al (2014) Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 24(8):1269PubMedCrossRefGoogle Scholar
  21. Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, Stürmer T (2012) Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol 32(1):114–119PubMedCrossRefGoogle Scholar
  22. Ge W, Jakobsson E (2018) Systems biology understanding of the effects of lithium on affective and neurodegenerative disorders. Front Neurosci 12:933PubMedPubMedCentralCrossRefGoogle Scholar
  23. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH (2013) Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 74:1101–1107PubMedCrossRefGoogle Scholar
  24. Greden JF (2001) The burden of disease for treatment-resistant depression. J Clin Psychiatry 62(Suppl 16):26–31PubMedGoogle Scholar
  25. Gulrez G, Badyal DK, Deswal RS, Sharma A (2012) Bupropion as an augmenting agent in patients of depression with partial response. Basic Clin Pharmacol Toxicol 110(3):227–230CrossRefGoogle Scholar
  26. Hobart M, Skuban A, Zhang P et al (2018a) A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry 79(4):17m12058Google Scholar
  27. Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H (2018b) Adjunctive brexpiprazole and functioning in major depressive disorder: a pooled analysis of six randomized studies using the Sheehan disability scale. Int J Neuropsychopharmacol 22(3):173–179Google Scholar
  28. Kautzky A, Dold M, Bartova L, Spies M, Kranz GS, Souery D et al (2019) Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatr Scand 139:78–88PubMedCrossRefGoogle Scholar
  29. Kessler D, Burns A, Tallon D, Lewis G, MacNeill S, Round J et al (2018) Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technol Assess 22(63)PubMedCrossRefGoogle Scholar
  30. Lewitzka U, Severus E, Bauer R, Ritter P, Müller-Oerlinghausen B, Bauer M (2015) The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review. Int J Bipolar Disord 3(1):32.  https://doi.org/10.1186/s40345-015-0032-2CrossRefPubMedGoogle Scholar
  31. Luan S, Wan H, Wang S, Li H, Zhang B (2017) Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat 13:609–620PubMedPubMedCentralCrossRefGoogle Scholar
  32. Luan S, Wan H, Zhang L, Zhao H (2018) Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat 14:467–477PubMedPubMedCentralCrossRefGoogle Scholar
  33. McAllister-Williams RH, Anderson IM, Finkelmeyer A, Gallagher P, Grunze HC, Haddad PM, Hughes T, Lloyd AJ, Mamasoula C, McColl E, Pearce S (2016) Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry 3:117–127PubMedCrossRefGoogle Scholar
  34. McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS et al (2014) Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 156:1–7PubMedCrossRefGoogle Scholar
  35. Mohamed S, Johnson GR, Chen P, et al (2017) Effect of antidepressant switching vs. augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA 318:132–145Google Scholar
  36. Mulder R, Hamilton A, Irwin L, Boyce P, Morris G, Porter RJ, Malhi GS (2018) Treating depression with adjunctive antipsychotics. Bipolar Disord (Suppl 2):17–24.  https://doi.org/10.1111/bdi.12701PubMedCrossRefPubMedCentralGoogle Scholar
  37. Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166(9):980–991PubMedCrossRefPubMedCentralGoogle Scholar
  38. Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C (2014) A systematic review and meta-analysis of lithium augmentation in tricyclic and second generation antidepressants in major depression. J Affect Disord 156:269–275CrossRefGoogle Scholar
  39. Nelson JC, Zhang P, Skuban A et al (2016) Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment. Curr Psychiatry Rev 12(3):278–290CrossRefGoogle Scholar
  40. Nemets B, Stahl Z, Belmaker RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159:477–479PubMedCrossRefGoogle Scholar
  41. Nierenberg AA, Fava M, Trivedi MH et al (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163:1519–1530PubMedCrossRefPubMedCentralGoogle Scholar
  42. Papakostas GI, Shelton RC, Smith J, Fava M (2007) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68:826–831PubMedCrossRefGoogle Scholar
  43. Papakostas GI, Fava M, Thase ME (2008) Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 63(7):699–704PubMedCrossRefPubMedCentralGoogle Scholar
  44. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M (2010) S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 167:942–948PubMedCrossRefGoogle Scholar
  45. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M (2012) L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 169:1267–1274PubMedCrossRefGoogle Scholar
  46. Papakostas GI, Ionescu DF (2015) Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry 20:1142–1150PubMedCrossRefGoogle Scholar
  47. Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK (2016) Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol 6(2):99–144.  https://doi.org/10.1177/2045125316629071. Epub 18 Feb 2016PubMedPubMedCentralCrossRefGoogle Scholar
  48. Pérez V, Gilaberte I, Faries D, Alvarez E, Artigas F (1997) Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349:1594–1597CrossRefGoogle Scholar
  49. Pérez V, Salavert A, Espadaler J et al (2017) Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry 17(1):250PubMedPubMedCentralCrossRefGoogle Scholar
  50. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al (2006a) STAR*D study team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354(12):1231–1242Google Scholar
  51. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, et al (2006b) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry 163:1905–1917PubMedCrossRefGoogle Scholar
  52. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M et al (2008) Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 65(8):870–880PubMedCrossRefGoogle Scholar
  53. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT et al (2011) Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168:689–701PubMedCrossRefGoogle Scholar
  54. Simon GE, Khandker RK, Ichikawa L, Operskalski BH (2006) Recovery from depression predicts lower health services costs. J Clin Psychiatry 67:1226–1231PubMedCrossRefGoogle Scholar
  55. Smith KA, Cipriani A. Lithium and suicide in mood disorders: updated meta-review of the scientific literature.Bipolar Disord. 2017 Nov;19(7):575–586Google Scholar
  56. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013) Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10:e1001403PubMedPubMedCentralCrossRefGoogle Scholar
  57. Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A et al (2013) Contribution of common genetic variants to antidepressant response. Biol Psychiatry 73(7):679–682.  https://doi.org/10.1016/j.biopsych.2012.10.030CrossRefPubMedGoogle Scholar
  58. Thase ME, Zhang P, Skuban A, Hobart M, Weiss C, Weiller E, Nelson JC (2016) Efficacy of adjunctive brexpiprazole in patients with major depressive disorder: a clinical overview. Curr Psychiatry Rev 12:291–301CrossRefGoogle Scholar
  59. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ (2006a) STAR*D study team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354(12):1243–1252PubMedCrossRefGoogle Scholar
  60. Trivedi MH, Rush AJ, Wisniewski SR et al (2006b) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163(1):28–40PubMedCrossRefGoogle Scholar
  61. Wang SM, Han C, Lee SJ et al (2016) Second generation antipsychotics in the treatment of major depressive disorder: an update. Chonnam Med J. 52(3):159–172PubMedPubMedCentralCrossRefGoogle Scholar
  62. WHO (2018) Depression fact sheet. https://www.who.int/en/news-room/fact-sheets/detail/depression. Accessed 17 Mar 2019
  63. Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L et al (2019) General predictors and moderators of depression remission: a VAST-D report. Am J Psychiatry Published online 4 May 2019Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.VA Northeast Ohio Healthcare System, Cleveland VA Medical CenterCase Western Reserve University School of MedicineClevelandUSA

Personalised recommendations